Detection of Neutralizing Antibodies in COVID-19 Patients from Steve Biko Academic Hospital Complex: A Pilot Study

A correlation between neutralization activity after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination and protection against coronavirus disease 2019 (COVID-19) has been demonstrated by several studies. Here, we detect SARS-CoV-2 neutralizing antibody (NAB) production in COVID...

Full description

Saved in:
Bibliographic Details
Published inCOVID Vol. 3; no. 7; pp. 999 - 1010
Main Authors Kgatle, Mankgopo, Chalwe, Joseph Musonda, van der Westhuizen, Donald, Xu, Shuting, Damane, Botle Precious, Mathebela, Precious, Ueckermann, Veronica, Mayaphi, Simnikiwe, Rodrigues, Hosana Gomes, Moura-Alves, Pedro, Ndlovu, Honest, Mzizi, Yonwaba, Zongo, Lusanda, Hairwadzi, Henry, Vorster, Mariza, Zeevaart, Jan Rijn, Sathekge, Mike
Format Journal Article
LanguageEnglish
Published MDPI AG 01.07.2023
Subjects
Online AccessGet full text

Cover

Loading…
Abstract A correlation between neutralization activity after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination and protection against coronavirus disease 2019 (COVID-19) has been demonstrated by several studies. Here, we detect SARS-CoV-2 neutralizing antibody (NAB) production in COVID-19 patients from the Steve Biko Academic Hospital complex (SBAH), South Africa (SA). Samples from COVID-19 patients (mild to severe) were collected. SARS-CoV-2 rapid assays, genotyping (Delta and Omicron variants) and enzyme-linked immunosorbent assays (ELISA) were performed. IBM® Statistical Package for the Social Sciences (SPSS®) version 28 was used for inferential statistical analysis, and the data were presented using the Prism9 software (version 9.4.1). A total of 137 laboratory-confirmed COVID-19 patients, 12 vaccine recipients and 8 unvaccinated participants were evaluated. The production of SARS-CoV-2 NABs was observed in some of the COVID-19 cases, mainly in severe cases, although this should be noted with caution due to the small sample size of this pilot study. NABs were also observed in asymptomatic participants, with the most being found in recipients (n = 6) of the BNT162b2 (Pfizer-BioNTech) COVID-19 vaccine. We found a strong presence of NABs in COVID-19 patients, specifically in mild and severe cases. Severe infection was associated with higher NAB production (82%).
AbstractList A correlation between neutralization activity after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination and protection against coronavirus disease 2019 (COVID-19) has been demonstrated by several studies. Here, we detect SARS-CoV-2 neutralizing antibody (NAB) production in COVID-19 patients from the Steve Biko Academic Hospital complex (SBAH), South Africa (SA). Samples from COVID-19 patients (mild to severe) were collected. SARS-CoV-2 rapid assays, genotyping (Delta and Omicron variants) and enzyme-linked immunosorbent assays (ELISA) were performed. IBM® Statistical Package for the Social Sciences (SPSS®) version 28 was used for inferential statistical analysis, and the data were presented using the Prism9 software (version 9.4.1). A total of 137 laboratory-confirmed COVID-19 patients, 12 vaccine recipients and 8 unvaccinated participants were evaluated. The production of SARS-CoV-2 NABs was observed in some of the COVID-19 cases, mainly in severe cases, although this should be noted with caution due to the small sample size of this pilot study. NABs were also observed in asymptomatic participants, with the most being found in recipients (n = 6) of the BNT162b2 (Pfizer-BioNTech) COVID-19 vaccine. We found a strong presence of NABs in COVID-19 patients, specifically in mild and severe cases. Severe infection was associated with higher NAB production (82%).
Author Mzizi, Yonwaba
Mayaphi, Simnikiwe
Sathekge, Mike
Xu, Shuting
Damane, Botle Precious
Chalwe, Joseph Musonda
Vorster, Mariza
Hairwadzi, Henry
Rodrigues, Hosana Gomes
van der Westhuizen, Donald
Ndlovu, Honest
Kgatle, Mankgopo
Zongo, Lusanda
Ueckermann, Veronica
Mathebela, Precious
Zeevaart, Jan Rijn
Moura-Alves, Pedro
Author_xml – sequence: 1
  givenname: Mankgopo
  surname: Kgatle
  fullname: Kgatle, Mankgopo
– sequence: 2
  givenname: Joseph Musonda
  orcidid: 0000-0001-9148-9224
  surname: Chalwe
  fullname: Chalwe, Joseph Musonda
– sequence: 3
  givenname: Donald
  surname: van der Westhuizen
  fullname: van der Westhuizen, Donald
– sequence: 4
  givenname: Shuting
  surname: Xu
  fullname: Xu, Shuting
– sequence: 5
  givenname: Botle Precious
  orcidid: 0000-0003-3060-5572
  surname: Damane
  fullname: Damane, Botle Precious
– sequence: 6
  givenname: Precious
  orcidid: 0000-0003-2794-0222
  surname: Mathebela
  fullname: Mathebela, Precious
– sequence: 7
  givenname: Veronica
  orcidid: 0000-0002-4419-3583
  surname: Ueckermann
  fullname: Ueckermann, Veronica
– sequence: 8
  givenname: Simnikiwe
  orcidid: 0000-0002-5453-4353
  surname: Mayaphi
  fullname: Mayaphi, Simnikiwe
– sequence: 9
  givenname: Hosana Gomes
  orcidid: 0000-0002-6122-0379
  surname: Rodrigues
  fullname: Rodrigues, Hosana Gomes
– sequence: 10
  givenname: Pedro
  orcidid: 0000-0003-4337-9113
  surname: Moura-Alves
  fullname: Moura-Alves, Pedro
– sequence: 11
  givenname: Honest
  surname: Ndlovu
  fullname: Ndlovu, Honest
– sequence: 12
  givenname: Yonwaba
  surname: Mzizi
  fullname: Mzizi, Yonwaba
– sequence: 13
  givenname: Lusanda
  orcidid: 0000-0001-7840-7386
  surname: Zongo
  fullname: Zongo, Lusanda
– sequence: 14
  givenname: Henry
  surname: Hairwadzi
  fullname: Hairwadzi, Henry
– sequence: 15
  givenname: Mariza
  surname: Vorster
  fullname: Vorster, Mariza
– sequence: 16
  givenname: Jan Rijn
  orcidid: 0000-0003-0794-3012
  surname: Zeevaart
  fullname: Zeevaart, Jan Rijn
– sequence: 17
  givenname: Mike
  orcidid: 0000-0002-2806-0625
  surname: Sathekge
  fullname: Sathekge, Mike
BookMark eNpNkFtLAzEUhIMoeH3zB-QHuJo9Zze78a3WSwtiBS-vS5qclOh2U7JpUX-91Yr0aYZh-GDmkO12oSPGTnNxjqjEhQkrb1FUQlSwww5AVpjVeQ67W36fnfT9mxAC6gpBwQGL15TIJB86Hhx_oGWKuvVfvpvxQZf8NFhPPfcdH05ex9dZrvijTp661HMXw5w_JVoRv_LvgQ-MtjT3ho9Cv_BJt3wY5ouWPi75gD_6NqR1e2k_j9me021PJ396xF5ub56Ho-x-cjceDu4zg4Apk7pUVEkyAK6wSgAYLGqopCxlYSWqwhlNVk0Loyzq9RqweSnFOnc1FAqP2HjDtUG_NYvo5zp-NkH75jcIcdbomLxpqbECJSGAds4WaO20qnCqoSzLXNeqxjXrbMMyMfR9JPfPy0Xzc3-zfT9-A7DpeTg
Cites_doi 10.1038/s41591-020-0869-5
10.1016/j.ebiom.2021.103622
10.1001/jama.2022.1393
10.3389/fimmu.2021.633184
10.3390/vaccines9121376
10.1038/s41591-022-01816-0
10.3390/vaccines11020224
10.1016/S0140-6736(21)02835-X
10.1001/jama.2020.1585
10.1186/s12985-023-01974-8
10.1038/s41591-021-01377-8
10.3389/fimmu.2022.928501
10.1093/ofid/ofac135
10.1126/science.abm8108
10.1016/j.jaci.2009.09.017
10.1002/bies.201200099
10.1056/NEJMoa2119658
10.1101/2021.07.19.452771
10.3389/fmicb.2021.803031
10.1371/journal.pone.0258421
10.3389/fimmu.2021.681449
10.7326/M20-5926
10.1126/science.abe1107
10.1080/25765299.2021.1903144
10.2147/IDR.S373183
10.1016/j.cca.2021.10.028
10.1007/s11302-021-09814-6
10.1002/iid3.580
10.1016/j.medj.2021.01.005
10.1016/j.ajpath.2020.08.009
10.1016/j.jcv.2022.105253
10.1038/s41586-021-03207-w
10.1038/s41591-020-1051-9
10.1056/NEJMra2206573
ContentType Journal Article
DBID AAYXX
CITATION
DOA
DOI 10.3390/covid3070072
DatabaseName CrossRef
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
DatabaseTitleList
CrossRef
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
DeliveryMethod fulltext_linktorsrc
EISSN 2673-8112
EndPage 1010
ExternalDocumentID oai_doaj_org_article_d036e322affd43ddb773ba25551a8983
10_3390_covid3070072
GroupedDBID AAYXX
ABDBF
AFZYC
ALMA_UNASSIGNED_HOLDINGS
CITATION
GROUPED_DOAJ
MODMG
M~E
OK1
ID FETCH-LOGICAL-c323t-6a59e76ec22f4d9022c3482766564d6394fcaed9b4c9d3a2922d156094ff82493
IEDL.DBID DOA
ISSN 2673-8112
IngestDate Wed Aug 27 01:28:03 EDT 2025
Tue Jul 01 02:20:29 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 7
Language English
License https://creativecommons.org/licenses/by/4.0
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c323t-6a59e76ec22f4d9022c3482766564d6394fcaed9b4c9d3a2922d156094ff82493
ORCID 0000-0003-3060-5572
0000-0003-0794-3012
0000-0002-4419-3583
0000-0001-9148-9224
0000-0002-6122-0379
0000-0003-4337-9113
0000-0003-2794-0222
0000-0001-7840-7386
0000-0002-5453-4353
0000-0002-2806-0625
OpenAccessLink https://doaj.org/article/d036e322affd43ddb773ba25551a8983
PageCount 12
ParticipantIDs doaj_primary_oai_doaj_org_article_d036e322affd43ddb773ba25551a8983
crossref_primary_10_3390_covid3070072
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2023-07-01
PublicationDateYYYYMMDD 2023-07-01
PublicationDate_xml – month: 07
  year: 2023
  text: 2023-07-01
  day: 01
PublicationDecade 2020
PublicationTitle COVID
PublicationYear 2023
Publisher MDPI AG
Publisher_xml – name: MDPI AG
References Velilla (ref_11) 2021; 12
Yan (ref_14) 2022; 12
Alejo (ref_18) 2022; 327
Zahid (ref_24) 2021; 28
Nam (ref_15) 2021; 9
Nehme (ref_2) 2021; 174
Ng (ref_25) 2020; 370
ref_35
ref_34
Acharya (ref_37) 2022; 9
Wang (ref_4) 2020; 323
Merad (ref_12) 2022; 375
Bonnet (ref_31) 2021; 73
Khoury (ref_13) 2021; 27
ref_39
Reynolds (ref_26) 2022; 15
Oh (ref_19) 2022; 155
Osterhaus (ref_9) 2021; 12
Pradenas (ref_22) 2021; 2
Pang (ref_6) 2021; 8
Barouch (ref_21) 2022; 387
Puhach (ref_38) 2022; 28
Lam (ref_17) 2020; 184
Klein (ref_10) 2012; 34
Dadras (ref_33) 2021; 10
ref_23
Bonilla (ref_8) 2010; 125
ref_1
He (ref_3) 2020; 26
Sejdic (ref_7) 2023; 20
Gaebler (ref_20) 2021; 591
Madhi (ref_28) 2022; 386
Arankalle (ref_36) 2022; 13
Padoan (ref_16) 2021; 523
ref_5
Huang (ref_32) 2020; 26
Gustine (ref_30) 2020; 191
Hasan (ref_29) 2021; 18
McIntyre (ref_27) 2021; 399
References_xml – volume: 26
  start-page: 672
  year: 2020
  ident: ref_3
  article-title: Temporal dynamics in viral shedding and transmissibility of COVID-19
  publication-title: Nat. Med.
  doi: 10.1038/s41591-020-0869-5
– volume: 73
  start-page: 103622
  year: 2021
  ident: ref_31
  article-title: Severe COVID-19 is characterized by the co-occurrence of moderate cytokine inflammation and severe monocyte dysregulation
  publication-title: Ebiomedicine
  doi: 10.1016/j.ebiom.2021.103622
– volume: 327
  start-page: 1085
  year: 2022
  ident: ref_18
  article-title: Prevalence and durability of SARS-CoV-2 antibodies among unvaccinated US adults by history of COVID-19
  publication-title: JAMA
  doi: 10.1001/jama.2022.1393
– ident: ref_5
– volume: 12
  start-page: 633184
  year: 2021
  ident: ref_11
  article-title: Antibody Responses in COVID-19: A Review
  publication-title: Front. Immunol.
  doi: 10.3389/fimmu.2021.633184
– ident: ref_35
  doi: 10.3390/vaccines9121376
– volume: 28
  start-page: 1491
  year: 2022
  ident: ref_38
  article-title: Infectious viral load in unvaccinated and vaccinated individuals infected with ancestral, Delta or Omicron SARS-CoV-2
  publication-title: Nat. Med.
  doi: 10.1038/s41591-022-01816-0
– volume: 8
  start-page: 47
  year: 2021
  ident: ref_6
  article-title: Understanding neutralising antibodies against SARS-CoV-2 and their implications in clinical practice
  publication-title: Mil. Med. Res.
– ident: ref_39
  doi: 10.3390/vaccines11020224
– volume: 399
  start-page: 406
  year: 2021
  ident: ref_27
  article-title: COVID-19 vaccine strategies must focus on severe disease and global equity
  publication-title: Lancet
  doi: 10.1016/S0140-6736(21)02835-X
– volume: 323
  start-page: 1061
  year: 2020
  ident: ref_4
  article-title: Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan, China
  publication-title: JAMA
  doi: 10.1001/jama.2020.1585
– volume: 20
  start-page: 14
  year: 2023
  ident: ref_7
  article-title: High titers of neutralizing SARS-CoV-2 antibodies six months after symptom onset are associated with increased severity in COVID-19 hospitalized patients
  publication-title: Virol. J.
  doi: 10.1186/s12985-023-01974-8
– volume: 27
  start-page: 1205
  year: 2021
  ident: ref_13
  article-title: Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection
  publication-title: Nat. Med.
  doi: 10.1038/s41591-021-01377-8
– volume: 13
  start-page: 1
  year: 2022
  ident: ref_36
  article-title: Immunogenicity of two COVID-19 vaccines used in India: An observational cohort study in health care workers from a tertiary care hospital
  publication-title: Front. Immunol.
  doi: 10.3389/fimmu.2022.928501
– volume: 9
  start-page: ofac135
  year: 2022
  ident: ref_37
  article-title: Viral Load Among Vaccinated and Unvaccinated, Asymptomatic and Symptomatic Persons Infected With the SARS-CoV-2 Delta Variant
  publication-title: Open Forum Infect. Dis.
  doi: 10.1093/ofid/ofac135
– volume: 375
  start-page: 1122
  year: 2022
  ident: ref_12
  article-title: The immunology and immunopathology of COVID-19
  publication-title: Science
  doi: 10.1126/science.abm8108
– ident: ref_1
– volume: 125
  start-page: S33
  year: 2010
  ident: ref_8
  article-title: Adaptive immunity
  publication-title: J. Allergy Clin. Immunol.
  doi: 10.1016/j.jaci.2009.09.017
– volume: 34
  start-page: 1050
  year: 2012
  ident: ref_10
  article-title: Sex influences immune responses to viruses, and efficacy of prophylaxis and treatments for viral diseases
  publication-title: Bioessays
  doi: 10.1002/bies.201200099
– volume: 386
  start-page: 1314
  year: 2022
  ident: ref_28
  article-title: Population Immunity and COVID-19 Severity with Omicron Variant in South Africa
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa2119658
– ident: ref_23
  doi: 10.1101/2021.07.19.452771
– volume: 12
  start-page: 803031
  year: 2022
  ident: ref_14
  article-title: Neutralizing antibodies and cellular immune responses against SARS-CoV-2 sustained one and a half years after natural infection
  publication-title: Front. Microbiol.
  doi: 10.3389/fmicb.2021.803031
– ident: ref_34
  doi: 10.1371/journal.pone.0258421
– volume: 12
  start-page: 681449
  year: 2021
  ident: ref_9
  article-title: Aging and Options to Halt Declining Immunity to Virus Infections
  publication-title: Front. Immunol.
  doi: 10.3389/fimmu.2021.681449
– volume: 174
  start-page: 723
  year: 2021
  ident: ref_2
  article-title: COVID-19 Symptoms: Longitudinal Evolution and Persistence in Outpatient Settings
  publication-title: Ann. Intern. Med.
  doi: 10.7326/M20-5926
– volume: 370
  start-page: 1339
  year: 2020
  ident: ref_25
  article-title: Preexisting and de novo humoral immunity to SARS-CoV-2 in humans
  publication-title: Science
  doi: 10.1126/science.abe1107
– volume: 28
  start-page: 225
  year: 2021
  ident: ref_24
  article-title: A review on COVID-19 vaccines: Stages of clinical trials, mode of actions and efficacy
  publication-title: Arab J. Basic Appl. Sci.
  doi: 10.1080/25765299.2021.1903144
– volume: 15
  start-page: 5167
  year: 2022
  ident: ref_26
  article-title: COVID-19 vaccination breakthrough infections in a real-world setting: Using community reporters to evaluate vaccine effectiveness
  publication-title: Infect. Drug Resist.
  doi: 10.2147/IDR.S373183
– volume: 523
  start-page: 446
  year: 2021
  ident: ref_16
  article-title: SARS-CoV-2 neutralizing antibodies after one or two doses of Comirnaty (BNT162b2, BioNTech/Pfizer): Kinetics and comparison with chemiluminescent assays
  publication-title: Clin. Chim. Acta
  doi: 10.1016/j.cca.2021.10.028
– volume: 18
  start-page: 13
  year: 2021
  ident: ref_29
  article-title: A novel definition and treatment of hyperinflammation in COVID-19 based on purinergic signalling
  publication-title: Purinergic Signal.
  doi: 10.1007/s11302-021-09814-6
– volume: 10
  start-page: e580
  year: 2021
  ident: ref_33
  article-title: The relationship between COVID-19 viral load and disease severity: A systematic review
  publication-title: Immun. Inflamm. Dis.
  doi: 10.1002/iid3.580
– volume: 2
  start-page: 313
  year: 2021
  ident: ref_22
  article-title: Stable neutralizing an-tibody levels 6 months after mild and severe COVID-19 episodes
  publication-title: Med
  doi: 10.1016/j.medj.2021.01.005
– volume: 191
  start-page: 4
  year: 2020
  ident: ref_30
  article-title: Immunopathology of Hyperinflammation in COVID-19
  publication-title: Am. J. Pathol.
  doi: 10.1016/j.ajpath.2020.08.009
– volume: 9
  start-page: 3
  year: 2021
  ident: ref_15
  article-title: Evaluation of Humoral Immune Response after SARS-CoV-2 Vaccination Using Two Binding Antibody Assays and a Neutralizing Antibody Assay
  publication-title: ASM J.
– volume: 184
  start-page: 476
  year: 2020
  ident: ref_17
  article-title: COVID-19-neutralizing antibodies predict disease severity and survival
  publication-title: Cell
– volume: 155
  start-page: 105253
  year: 2022
  ident: ref_19
  article-title: Neutralizing antibody responses in vaccinated and unvaccinated individuals infected with Omicron BA.1 variant
  publication-title: J. Clin. Virol.
  doi: 10.1016/j.jcv.2022.105253
– volume: 591
  start-page: 639
  year: 2021
  ident: ref_20
  article-title: Evolution of antibody immunity to SARS-CoV-2
  publication-title: Nature
  doi: 10.1038/s41586-021-03207-w
– volume: 26
  start-page: 1636
  year: 2020
  ident: ref_32
  article-title: An inflammatory cytokine signature predicts COVID-19 severity and survival
  publication-title: Nat. Med.
  doi: 10.1038/s41591-020-1051-9
– volume: 387
  start-page: 1011
  year: 2022
  ident: ref_21
  article-title: COVID-19 vaccines—Immunity, variants, boosters
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMra2206573
SSID ssj0002873292
Score 2.2244987
Snippet A correlation between neutralization activity after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination and protection against coronavirus...
SourceID doaj
crossref
SourceType Open Website
Index Database
StartPage 999
SubjectTerms COVID-19
ELISA
neutralizing antibodies
SARS-CoV-2
South Africa
Steve Biko Academic Hospital
Title Detection of Neutralizing Antibodies in COVID-19 Patients from Steve Biko Academic Hospital Complex: A Pilot Study
URI https://doaj.org/article/d036e322affd43ddb773ba25551a8983
Volume 3
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1LS8NAEF6kJy-iqFhfzEGPoWl2k0289YkKrT1Y6S3sE6olkZqCevC3O7tppZ68eMlhCCHMTDLfLN98Q8gV2mMhuAnSxCYBU0oFgocyoCaUbYU4SXrFm9E4uZ2y-1k821r15ThhtTxw7biWxl-swawT1mpGtZacUykQCMdtkWap1_nEmrfVTD37IyNOoyyqme4U-_qWcnNtLsFDHv2qQVtS_b6mDPfJ3hoMQqd-iQOyY4pDsuybyvOjCigtjM3Kn0V8YomBTlHNZel4fzAvoPfwdNcP2hlMam3UN3CzIuD3lEF3_lLChvwOm-0g4D7_hXm_gQ5M5ouyAscj_Dgi0-HgsXcbrDcjBIpGtAoSEWeGJ0ZFkWU6wzqsnEgNTxCdMY2gg1kljM4kU5mmAj0RaTcyjXabYsNFj0mjKAtzQiBBPMEMp0yxlFmhZJwqbZVE6GJjxcImud74Kn-tBTBybBycT_NtnzZJ1zny5x4nW-0NGMx8Hcz8r2Ce_sdDzsiu2wlfc2rPSaNarswFIodKXvokwevoa_ANZ4TDcg
linkProvider Directory of Open Access Journals
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Detection+of+Neutralizing+Antibodies+in+COVID-19+Patients+from+Steve+Biko+Academic+Hospital+Complex%3A+A+Pilot+Study&rft.jtitle=COVID&rft.au=Mankgopo+Kgatle&rft.au=Joseph+Musonda+Chalwe&rft.au=Donald+van+der+Westhuizen&rft.au=Shuting+Xu&rft.date=2023-07-01&rft.pub=MDPI+AG&rft.eissn=2673-8112&rft.volume=3&rft.issue=7&rft.spage=999&rft.epage=1010&rft_id=info:doi/10.3390%2Fcovid3070072&rft.externalDBID=DOA&rft.externalDocID=oai_doaj_org_article_d036e322affd43ddb773ba25551a8983
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2673-8112&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2673-8112&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2673-8112&client=summon